I Ross McDougall

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Metastatic struma ovarii: the burden of truth
    I Ross McDougall
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Clin Nucl Med 31:321-4. 2006
  2. ncbi request reprint F-18 FDG PET/CT in the management of thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Nucl Med 32:690-5. 2007
  3. ncbi request reprint F-18 FDG PET/CT imaging of a subcutaneous scalp metastasis from primary carcinoma of the thyroid
    Ryan D Niederkohr
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford University Hospital and Clinics, Stanford, CA 94305 5281, USA
    Clin Nucl Med 32:162-4. 2007
  4. ncbi request reprint Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma
    Andrew Quon
    Division of Nuclear Medicine, Department of Radiology, Stanford University Medical Center, Stanford, California 94305, USA
    J Nucl Med 48:58S-67S. 2007
  5. ncbi request reprint F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Clin Nucl Med 32:13-5. 2007
  6. ncbi request reprint Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning"
    Judy E Kalinyak
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Nucl Med Commun 25:883-9. 2004
  7. ncbi request reprint Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans
    Jason B Cohen
    Division of Nuclear Medicine, Stanford University School of Medicine, California 94305 5281, USA
    Nucl Med Commun 25:129-34. 2004
  8. doi request reprint Thyroid stunning: fact or fiction?
    I Ross McDougall
    Division of Nuclear Medicine and Molecular Imaging, Stanford University Hospital and Clinics, Stanford, CA, USA
    Semin Nucl Med 41:105-12. 2011
  9. doi request reprint Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma
    Erik Mittra
    Division of Nuclear Medicine, Stanford Hospitals and Clinics, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 36:1952-9. 2009
  10. doi request reprint 18F-FDG PET/CT demonstration of a liver metastasis in a patient with papillary thyroid cancer
    Camila Mosci
    Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Nucl Med 37:e234-6. 2012

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Metastatic struma ovarii: the burden of truth
    I Ross McDougall
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Clin Nucl Med 31:321-4. 2006
    ..By a process of elimination, a diagnosis of metastatic struma ovarii was established. Treatment of metastatic thyroid cancer from struma ovarii, including removal of the normal thyroid and administration of I-131, is presented...
  2. ncbi request reprint F-18 FDG PET/CT in the management of thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Clin Nucl Med 32:690-5. 2007
    ..We reviewed our experience with F-18 FDG PET/CT in thyroid cancer, with an emphasis on correlation with Tg, and maximum standardized uptake values (SUV). We also analyzed the role of thyroid stimulating hormone (TSH) on PET/CT results...
  3. ncbi request reprint F-18 FDG PET/CT imaging of a subcutaneous scalp metastasis from primary carcinoma of the thyroid
    Ryan D Niederkohr
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford University Hospital and Clinics, Stanford, CA 94305 5281, USA
    Clin Nucl Med 32:162-4. 2007
  4. ncbi request reprint Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma
    Andrew Quon
    Division of Nuclear Medicine, Department of Radiology, Stanford University Medical Center, Stanford, California 94305, USA
    J Nucl Med 48:58S-67S. 2007
    ....
  5. ncbi request reprint F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, California 94305, USA
    Clin Nucl Med 32:13-5. 2007
    ..An adrenal metastasis was identified on an F-18 FDG PET/CT scan in a patient with anaplastic thyroid cancer. There are very few reports of thyroid cancer, even anaplastic thyroid cancer, metastasizing to the adrenal...
  6. ncbi request reprint Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning"
    Judy E Kalinyak
    Division of Nuclear Medicine, Stanford University Medical Center, Stanford, CA 94305, USA
    Nucl Med Commun 25:883-9. 2004
  7. ncbi request reprint Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans
    Jason B Cohen
    Division of Nuclear Medicine, Stanford University School of Medicine, California 94305 5281, USA
    Nucl Med Commun 25:129-34. 2004
    ..This study evaluated pairs of diagnostic 123I and post-therapy 131I scans for differences in patterns of radioiodine uptake...
  8. doi request reprint Thyroid stunning: fact or fiction?
    I Ross McDougall
    Division of Nuclear Medicine and Molecular Imaging, Stanford University Hospital and Clinics, Stanford, CA, USA
    Semin Nucl Med 41:105-12. 2011
    ..Larger diagnostic doses and longer delays to therapy appear to increase the likelihood of stunning. The stunning effect of early-absorbed radiation from the therapy should also be considered...
  9. doi request reprint Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma
    Erik Mittra
    Division of Nuclear Medicine, Stanford Hospitals and Clinics, 300 Pasteur Dr, Room H 0101, Stanford, CA 94305, USA
    Eur J Nucl Med Mol Imaging 36:1952-9. 2009
    ..Only a limited number of studies have evaluated the efficacy of 18F-FDG PET/CT for recurrent cervical carcinoma, which this study seeks to expand upon...
  10. doi request reprint 18F-FDG PET/CT demonstration of a liver metastasis in a patient with papillary thyroid cancer
    Camila Mosci
    Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center, Stanford, CA 94305, USA
    Clin Nucl Med 37:e234-6. 2012
    ..These were medullary thyroid carcinomas (MTC) or poorly differentiated cancers. There are no reports describing liver metastasis from PTC diagnosed by FDG PET/CT...
  11. ncbi request reprint Incidental gallbladder visualization on nonhepatobiliary nuclear medicine studies: case series and review of the literature
    Ryan D Niederkohr
    Division of Nuclear Medicine, Stanford University Hospital and Clinics, Stanford, California 94305, USA
    Clin Nucl Med 32:915-9. 2007
    ..The potential for misdiagnosis and the steps taken to avoid this are discussed...
  12. ncbi request reprint Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin
    Ryan D Niederkohr
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H 0101, Stanford, CA 94305 5281, USA
    Eur J Nucl Med Mol Imaging 34:363-7. 2007
    ..We assessed the reproducibility of radioiodine uptake, serum thyrotropin (TSH), and stimulated serum thyroglobulin (Tg) levels after rhTSH administration...
  13. ncbi request reprint Treatment of micropapillary carcinoma of the thyroid: where do we draw the line?
    I Ross McDougall
    Division of Nuclear Medicine and Molecular Imaging Program at Stanford, Department of Radiology, Stanford University Hospital and Clinics, 300 Pasteur Drive, Stanford, CA 94305, USA
    Thyroid 17:1093-6. 2007
    ..We believe that, apart from lobectomy, these therapies were not justified. We draw attention to this to provide a topic for debate and to attempt to prevent this happening to other patients...
  14. ncbi request reprint The interpretation of 131I scans in the evaluation of thyroid cancer, with an emphasis on false positive findings
    M R Carlisle
    Division of Nuclear Medicine, Stanford University Medical Center, California 94305, USA
    Nucl Med Commun 24:715-35. 2003
    ..A variety of cases illustrating true positive, true negative, and false positive findings is presented in this review, and the causes and consequences of misinterpretation of radioiodine scans are discussed...
  15. ncbi request reprint Treatment of thyrotoxicosis
    Andrei Iagaru
    Division of Nuclear Medicine and Molecular Imaging Program at Stanford, Department of Radiology, Stanford University Medical Center, Stanford, California, USA
    J Nucl Med 48:379-89. 2007
    ..The different approaches to application of (131)I treatment are described. Treatment with (131)I has been found to be cost-effective, safe, and reliable...
  16. doi request reprint Uncommon causes of thyrotoxicosis
    Erik S Mittra
    Division of Nuclear Medicine and Molecular Imaging Program at Stanford, Department of Radiology, Stanford University Hospital and Clinics, Stanford, California 94305 5281, USA
    J Nucl Med 49:265-78. 2008
    ..Thyrotropin and free thyroxine should be measured and, when the latter is normal, the free triiodothyronine level should be obtained. Measurement of the uptake of (123)I is recommended for most patients...
  17. ncbi request reprint Burkitt's lymphoma presenting as a rapidly growing thyroid mass
    Judith E Kalinyak
    Thyroid Clinic, Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California, USA
    Thyroid 16:1053-7. 2006
    ..His presentation highlights the urgency in diagnosis and provides an opportunity to review a rare type of primary thyroid lymphoma...
  18. ncbi request reprint F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas
    Andrei Iagaru
    Division of Nuclear Medicine, Department of Radiology, Stanford Hospital and Clinics, Stanford, California, USA
    Clin Nucl Med 31:754-60. 2006
    ..Therefore, we were prompted to review our experience with F-18 FDG PET/CT in OSTS...
  19. ncbi request reprint Elephantiasic pretibial myxedema
    Jason B Cohen
    Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California 94305 5281, USA
    Thyroid 14:237-8. 2004
  20. ncbi request reprint Modern management of differentiated thyroid cancer
    Jason B Cohen
    Division of Nuclear Medicine and Thyroid Clinic, Stanford University Medical Center, Stanford, CA 94305, USA
    Cancer Biother Radiopharm 18:689-705. 2003
    ..In patients with elevated thyroglobulin and negative scans with radioactive iodine, there is increasing evidence that positron emission tomography (PET) is helpful in locating the site of thyroglobulin production...
  21. ncbi request reprint Common and uncommon sonographic features of papillary thyroid carcinoma
    Bryan K Chan
    Department of Radiology, Stanford University School of Medicine, Stanford, California 94305, USA
    J Ultrasound Med 22:1083-90. 2003
    ..To determine the relative frequency of various sonographic findings in papillary carcinoma of the thyroid...
  22. ncbi request reprint Intraoperative ultrasonography improves identification of recurrent thyroid cancer
    John K Karwowski
    Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA
    Surgery 132:924-8; discussion 928-9. 2002
    ..We hypothesized that intraoperative ultrasonography would aid in the localization of recurrent thyroid cancer and would enhance the ability to perform a complete resection...
  23. ncbi request reprint Needle track seeding of papillary thyroid carcinoma from fine needle aspiration biopsy. A case report
    John K Karwowski
    Department of Surgery, MSLS, Room P214, 1201 Welch Road, Stanford University School of Medicine, Stanford, California 94305, USA
    Acta Cytol 46:591-5. 2002
    ..Fine needle aspiration (FNA) biopsy has become accepted as the first-line test in the evaluation of thyroid nodules. Local recurrence of thyroid cancer from needle track seeding is an extremely rare complication of thyroid FNA...
  24. ncbi request reprint The role of radioactive iodine in the treatment of well-differentiated thyroid cancer
    Ronald J Weigel
    Department of Surgery, University of Iowa, Carver College of Medicine, 200 Hawkins Drive, Room 1516 JCP, Iowa City, IA 52242 1086, USA
    Surg Oncol Clin N Am 15:625-38. 2006
    ..Therefore, whether the patient will have a better prognosis after treatment with 131I and whether the benefits of treatment are greater than the side effects must be determined for every patient...
  25. ncbi request reprint ATA Guidelines: do patients with stage I thyroid cancer benefit from (131)I?
    I Ross McDougall
    Thyroid 17:595-6; author reply 596-7. 2007
  26. ncbi request reprint How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism?
    Judith E Kalinyak
    J Clin Endocrinol Metab 88:975-7. 2003